National Academy of Medicine Elects 100 New Members - DF/HCC Members Included
October 29, 2024
Several DF/HCC members were elected to the National Academy of Medicine, including:
Bob S. Carter, MD, PhD, William and Elizabeth Sweet Professor of Neurosurgery, Harvard Medical School and Massachusetts General Hospital, Boston. For contributions to neurosurgery, neuro-oncology, central nervous system gene-/cell-based therapies, including the creation of CAR T cells against human glioblastoma (hGBM), discovery of extracellular vesicles in hGBM, and “first in man” use of induced pluripotent stem cell derived dopaminergic neurons for Parkinson’s disease.
Marcia Carmen Haigis, PhD, professor, department of cell biology, Harvard Medical School, Boston. For leadership and pioneering studies in cellular metabolism, elucidating how metabolites contribute to normal physiology, aging, cancer, and anti-tumor immune control. Her discoveries informed how diet and age alter metabolite interactions, leading to disease.
David Pellman, MD, Howard Hughes Medical Institute investigator and professor of cell biology and pediatrics, Dana-Farber Cancer Institute and Harvard Medical School, Boston. For identifying the mechanistic basis for mutational processes that generate a large fraction of the structural and numerical chromosome abnormalities in cancer and certain congenital diseases. In particular, his discovery of a mechanism explaining chromothripsis is considered a landmark in cancer genetics.
Hao Wu, PhD, senior investigator, Program in Cellular and Molecular Medicine, Boston Children’s Hospital; and Asa and Patricia Springer Professor, department of biological chemistry and molecular pharmacology, Harvard Medical School, Boston. For discovering supramolecular complexes (signalosomes) as central organizing structures that mediate signal transduction in innate immunity. Her studies led to a paradigm shift in signal transduction and new therapeutic strategies for inflammation and cancer where small molecules are developed to keep the signaling proteins in a monomeric, inactive state.